• 1
    Prat J, Gallardo A, Cuatrecasas M, Catasus L. Endometrial carcinoma: pathology and genetics. Pathology 2007; 39: 7287.
  • 2
    Lee NK, Cheung MK, Shin JY et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol 2007; 109: 65562.
  • 3
    Burke TW, Fowler WC Jr, Morrow CP. Clinical aspects of risk in women with endometrial carcinoma. J Cell Biochem Suppl 1995; 23: 1316.
  • 4
    Benshushan A. Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol 2004; 117: 1327.
  • 5
    Minaguchi T, Nakagawa S, Takazawa Y et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 2007; 248: 11222.
  • 6
    Hahn HS, Yoon SG, Hong JS et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009; 19: 106873.
  • 7
    Yamazawa K, Hirai M, Fujito A et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007; 22: 19538.
  • 8
    Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004; 95: 1338.
  • 9
    Hoekstra AV, Kim JJ, Keh P, Schink JC. Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report. J Reprod Med 2008; 53: 86973.
  • 10
    Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med 2010; 28: 8190.
  • 11
    Kaku T, Yoshikawa H, Tsuda H et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001; 167: 3948.
  • 12
    Zhao S, Chen X, Lu X, Yu Y, Feng Y. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma. Gynecol Oncol 2007; 105: 4554.
  • 13
    Wang H, Isaksson E, von Schoultz B, Cline JM, Sahlin L. Effect of long-term treatment with steroid hormones or tamoxifen on the progesterone receptor and androgen receptor in the endometrium of ovariectomized cynomolgus macaques. Reprod Biol Endocrinol 2003; 1: 7.
  • 14
    Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 2006; 12: 1013s8s.
  • 15
    Wang S, Pudney J, Song J, Mor G, Schwartz PE, Zheng W. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia – precursor of endometrial cancer. Gynecol Oncol 2003; 88: 10817.
  • 16
    Chen X, Zhang Z, Feng Y et al. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Mod Pathol 2009; 22: 699708.
  • 17
    Vereide AB, Kaino T, Sager G, Arnes M, Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 2006; 101: 21423.
  • 18
    Daniel AR, Qiu M, Faivre EJ, Ostrander JH, Skildum A, Lange CA. Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids 2007; 72: 188201.
  • 19
    Wu Y, Shi X, Guo SW. The knockdown of progesterone receptor isoform B (PR-B) promotes proliferation in immortalized endometrial stromal cells. Fertil Steril 2008; 90: 13203.
  • 20
    Saitoh M, Ohmichi M, Takahashi K et al. Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology 2005; 146: 491725.
  • 21
    Ballare C, Vallejo G, Vicent GP, Saragueta P, Beato M. Progesterone signaling in breast and endometrium. J Steroid Biochem Mol Biol 2006; 102: 210.
  • 22
    Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003; 17: 57588.
  • 23
    Fujiwara M, Izuishi K, Sano T et al. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res 2008; 27: 76.
  • 24
    Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6: 8806.
  • 25
    Smid-Koopman E, Kuhne LC, Hanekamp EE et al. Progesterone-induced inhibition of growth and differential regulation of gene expression in PRA- and/or PRB-expressing endometrial cancer cell lines. J Soc Gynecol Investig 2005; 12: 28592.
  • 26
    Santen RJ. Risk of breast cancer with progestins: critical assessment of current data. Steroids 2003; 68: 95364.
  • 27
    Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003; 148: 28192.
  • 28
    Safe S, Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 2008; 41: 26375.
  • 29
    Zhang L, Li X, Zhao L, Zhang G, Wang J, Wei L. Nongenomic effect of estrogen on the MAPK signaling pathway and calcium influx in endometrial carcinoma cells. J Cell Biochem 2009; 106: 55362.
  • 30
    Losel RM, Falkenstein E, Feuring M et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 2003; 83: 9651016.
  • 31
    Hanekamp EE, Gielen SC, Smid-Koopman E et al. Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer. Clin Cancer Res 2003; 9: 41909.
  • 32
    Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 398697.
  • 33
    McMillan J, Fatehi-Sedeh S, Sylvia VL et al. Sex-specific regulation of growth plate chondrocytes by estrogen is via multiple MAP kinase signaling pathways. Biochim Biophys Acta 2006; 1763: 38192.
  • 34
    Karteris E, Zervou S, Pang Y et al. Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol 2006; 20: 151934.
  • 35
    Dressing GE, Thomas P. Identification of membrane progestin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer. Steroids 2007; 72: 1116.
  • 36
    Ashley RL, Clay CM, Farmerie TA, Niswender GD, Nett TM. Cloning and characterization of an ovine intracellular seven transmembrane receptor for progesterone that mediates calcium mobilization. Endocrinology 2006; 147: 41519.
  • 37
    Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008; 112: 4657.
  • 38
    Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr Relat Cancer 2006; 13: 90519.
  • 39
    Sonoo H, Kurebayashi J. Endocrine therapy for advanced or recurrent breast cancer. Gan To Kagaku Ryoho 2001; 28: 90916.
  • 40
    Navo MA, Smith JA, Gaikwad A, Burke T, Brown J, Ramondetta LM. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol 2008; 62: 4839.
  • 41
    Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1: 70717.
  • 42
    Elit L, Hirte H. Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr Opin Obstet Gynecol 2002; 14: 6773.
  • 43
    Susumu N, Aoki D, Suzuki N, Nozawa S. Hormonal therapy for endometrial adenocarcinoma. Gan To Kagaku Ryoho 2001; 28: 93445.
  • 44
    Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 1998; 3: 8594.
  • 45
    Tokunaga E, Oki E, Kimura Y et al. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat 2007; 101: 24957.
  • 46
    Tokunaga E, Kimura Y, Mashino K et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006; 13: 13744.